1. Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms
- Author
-
Martina Haberecker, Marco Matteo Bühler, Alicia Pliego Mendieta, Roman Guggenberger, Fabian Arnold, Eva Markert, Markus Rechsteiner, Martin Zoche, Christian Britschgi, Chantal Pauli, University of Zurich, and Pauli, Chantal
- Subjects
DNA Helicases ,Nuclear Proteins ,Sarcoma ,610 Medicine & health ,SMARCB1 Protein ,Chromatin Assembly and Disassembly ,Immunohistochemistry ,Pathology and Forensic Medicine ,2734 Pathology and Forensic Medicine ,10049 Institute of Pathology and Molecular Pathology ,10032 Clinic for Oncology and Hematology ,Biomarkers, Tumor ,Humans ,Retrospective Studies ,Transcription Factors - Abstract
The switch/sucrose-non-fermenting (SWI/SNF) complex is an ATP-dependent chromatin remodeling complex that plays important roles in DNA repair, transcription and cell differentiation. This complex consists of multiple subunits and is of particular interest in thoracic malignancies due to frequent subunit alteration of SMARCA4 (BRG1). Much less is known about SMARCB1 (INI1) deficient intrathoracic neoplasms, which are rare, often misclassified and understudied. In a retrospective analysis of 1479 intrathoracic malignant neoplasms using immunohistochemistry for INI1 (SMARCB1) on tissue micro arrays (TMA) and a search through our hospital sarcoma database, we identified in total nine intrathoracic, INI1 deficient cases (n = 9). We characterized these cases further by additional immunohistochemistry, broad targeted genomic analysis, methylation profiling and correlated them with clinical and radiological data. This showed that genomic SMARCB1 together with tumor suppressor alterations drive tumorigenesis in some of these cases, rather than epigenetic changes such as DNA methylation. A proper diagnostic classification, however, remains challenging. Intrathoracic tumors with loss or alteration of SMARCB1 (INI1) are highly aggressive and remain often underdiagnosed due to their rarity, which leads to false diagnostic interpretations. A better understanding of these tumors and proper diagnosis is important for better patient care as clinical trials and more targeted therapeutic options are emerging.
- Published
- 2022